What is Golomb & Honik?
Golomb & Honik, P.C. operates as a specialized legal practice with a distinct focus on beryllium litigation and pharmaceutical liability, most notably regarding VIOXX-related health complications. The firm occupies a critical niche in the personal injury landscape, providing essential legal advocacy for individuals suffering from severe health consequences due to toxic exposure or defective medical products. Their business model relies on deep domain expertise in mass torts, allowing them to navigate the intricate regulatory and medical evidence required to secure justice for their clients. By maintaining a focus on these high-barrier-to-entry legal domains, the firm has established itself as a formidable entity in the plaintiff-side litigation market.
How much funding has Golomb & Honik raised?
Golomb & Honik has raised a total of $372K across 2 funding rounds:
Debt
$150K
Debt
$222K
Debt (2020): $150K with participation from PPP
Debt (2021): $222K led by PPP
Key Investors in Golomb & Honik
PPP
Public-Private Partnership
What's next for Golomb & Honik?
With the infusion of $222K, Golomb & Honik, P.C. is well-positioned to scale its litigation infrastructure and enhance its case evaluation capabilities. The firm's strategic trajectory suggests a continued commitment to expanding its reach in mass tort litigation, likely focusing on optimizing the discovery process and strengthening its expert witness networks. As the firm moves into this next phase of growth, the focus will remain on maximizing recovery for clients while maintaining the operational efficiency required to manage large-scale, complex legal dockets. This capital deployment serves as a catalyst for sustained influence in the personal injury sector, ensuring the firm remains at the forefront of pharmaceutical and industrial liability advocacy.
See full Golomb & Honik company page
